NCT00266227

A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 559 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid arthritis (RA) who are receiving Methotrexate (MTX).

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	placebo	Intravenous repeating dose
DRUG	rituximab	Intravenous repeating dose
DRUG	methotrexate	Oral or parenteral repeating dose
DRUG	folate	Intravenous repeating dose

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-10-01
• First posted: 2005-12-16
• Last updated: 2013-10-25
• Results posted: 2009-05-25